Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics
SYDNEY--(BUSINESS WIRE)--Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams' partnership and sets a benchmark for CRO–biotech partnerships.
Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B.
Share
The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals.
Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, accepted the award on behalf of Novotech at the Citeline Awards ceremony held on May 8, 2025, in Boston. Katie Tarashuck, Vice President of Finance at Tune Therapeutics, attended as a partner representative.
Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and therapeutic expertise with Tune's innovative scientific platform and agile development strategy.
'This recognition from Citeline reflects not only the strength of our partnership with Tune Therapeutics but also the dedication of our global teams to help bring novel therapies to patients faster,' said Dr. John Moller, CEO of Novotech. 'We are honored to collaborate with visionary biotech companies like Tune and look forward to continuing to deliver clinical excellence across the development spectrum.'
'Tune is delighted to receive this partnership award with Novotech," said Dr. Heidi Zhang, Chief Development Officer at Tune Therapeutics. "Together, we have achieved a global first in bringing this epigenome editing therapy to the clinic, and new hope to over 250 million people living with CHB worldwide.'
The award acknowledges Novotech's ability to align closely with biotech partners, applying its regulatory and therapeutic expertise to support the effective delivery of clinical trials across varied global settings.
'The strength of this collaboration,' added Dr. Zhang, 'lies in our shared commitment to transparency, willingness to confront challenges directly, and ability to act quickly and effectively as one team.'
About Novotech
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member visit www.Novotech-CRO.com.
epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA. Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common and chronic diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
5 days ago
- Medscape
Metabolic Issues May Affect Liver Fibrosis in Hepatitis B
Patients with untreated chronic hepatitis B who had metabolic comorbidities were at a higher risk for advanced liver fibrosis and were less likely to see improvement with antiviral therapy than those without such comorbidities. METHODOLOGY: Researchers investigated the association between the presence of concurrent metabolic comorbidities and the severity of liver fibrosis in 3179 patients with untreated chronic hepatitis B (median age, 37 years; 72.2% men) using data from two tertiary clinics in the Netherlands and Canada and six global clinical trials. All patients underwent an initial liver biopsy, and 1307 of the patients enrolled in the clinical trials underwent a second biopsy 48-72 weeks after starting antiviral therapy. Biopsies were analyzed by experienced pathologists. Advanced fibrosis was defined as having METAVIR stages F3-F4, and nonadvanced fibrosis as having METAVIR stages F0-F2. Progression or regression of fibrosis was determined by an increase or decrease in fibrosis of at least one METAVIR stage from baseline, respectively. The presence of metabolic comorbidities (overweight, hypertension, diabetes, and dyslipidemia) was assessed using chart reviews and patient histories. TAKEAWAY: At baseline, metabolic comorbidities were present in 54.8% of patients, and advanced fibrosis was present in 24.4% of patients. The presence of metabolic comorbidities was independently associated with an increased risk for advanced fibrosis (adjusted odds ratio [aOR] for one comorbidity, 1.115; aOR for two or more comorbidities, 1.627; P = .006). = .006). The presence of metabolic comorbidities was also independently associated with reduced odds of regression from advanced to nonadvanced fibrosis after initiating antiviral therapy (aOR for one comorbidity, 0.79; aOR for two or more comorbidities, 0.26; P = .025). = .025). Progression to advanced fibrosis during antiviral therapy was observed in 9.8% of patients with one metabolic comorbidity and 14.3% of those with two or more metabolic comorbidities compared with 4.6% of those without metabolic comorbidities ( P = .001). IN PRACTICE: 'These findings provide solid support for the recently published World Health Organization HBV [hepatitis B virus] guideline, which underlines the importance of identifying and managing metabolic comorbidities in CHB [chronic hepatitis B] patients, as these comorbidities increase the risk of fibrosis progression and HCC [hepatocellular carcinoma] development,' the study authors wrote. SOURCE: The study, led by Lisa M. van Velsen, MD, Department of Gastroenterology & Hepatology, Erasmus Medical Center in Rotterdam, the Netherlands, was published online in Clinical Gastroenterology and Hepatology . LIMITATIONS: Information on hepatic steatosis was unavailable for the clinical trial patients. The presence of metabolic comorbidities was determined on the basis of a retrospective review of medical histories and medications, potentially leading to underdiagnosis of the conditions. Changes or development of metabolic comorbidities during follow-up could not be accounted for. DISCLOSURES: This study was sponsored by the Foundation for Liver and Gastrointestinal Research, and the data for the analyses were shared by Roche and Gilead Sciences. Several authors reported receiving research support or grants, consulting and/or speaking fees, honoraria, or contracts from pharmaceutical and biotechnology companies, including Roche and Gilead Sciences. One author reported being employed by Roche, and two authors reported being employed by Gilead Sciences.
Hamilton Spectator
5 days ago
- Hamilton Spectator
Catching Babies at Home – Cree midwifery celebrates historic milestone
An amendment to provincial regulations governing midwifery that took effect May 22 enables Indigenous trainees in community-based programs to provide full perinatal care throughout pregnancy, birth and new life. The change follows a campaign by the Cree Health Board, the Inuulitsivik Health Centre, the Ordre des sages-femmes du Québec and other organizations. 'We changed the law,' said Jasmine Chatelain, managing director of the CHB midwifery education program. 'Now our students are no longer limited and can learn all requirements for becoming a licensed midwife. The by-product is that Indigenous people can become midwives.' The health board's groundbreaking midwifery training program, Eeyou Istchee Pimâtîsuwin Chiskutimâchuwin (EIPC), launched last July with four learners in Chisasibi and one in Waskaganish. But they were legally restricted from delivering a baby and other procedures, such as injections and vaginal exams. The CHB hired students as Primary Care Community Representatives to provide counselling, take blood pressure, weigh babies, and check an unborn baby's position in the womb. Learning side-by-side with practicing midwives, they supported childbirth with what Chatelain calls 'four-handed catches'. 'Our program is focused on learning by doing so every single client has a student who follows them,' Chatelain explained. 'They do all the pre-natal and post-natal visits, a lot of the counselling and education, partly because they speak Cree. Our students can go on medevacs when women are transferred in labour or for something urgent.' However, before the regulatory change, only students in a Trois-Rivières university program and immigrating midwives in approved bridging programs were allowed to perform many professional acts. Despite Nunavik's longstanding community education program, Indigenous trainees were completely omitted from the law. The Ordre des sages-femmes du Québec regulates midwifery acts in the province, and were instrumental partners in lobbying the government to change the law. The OSFQ also collaborated with the EIPC program to ensure Cree graduates have equivalent competencies to university programs. 'We could not have done this without them,' Chatelain asserted. 'They've been very outspoken about being in this tricky position, responsible for public safety and wanting to be part of reconciliation, supporting Indigenous self-determination.' Several individuals and organizations issued letters of support for the regulatory change, including the National Council of Indigenous Midwives. It currently applies to four Indigenous midwifery programs running in Quebec's Cree, Inuit, Akwesasne and Innu communities. While expectant mothers from Nunavik were sent to Moose Factory starting in the 1970s, women began refusing to leave and communities mobilized to create the Inuulitsivik Midwifery Service in 1986. The EIPC program worked extensively with Inuulitisivik education coordinator Kimberly Moorhouse and her team to develop its curriculum. As the self-paced program requires trainees to attend 60 births, they will have access to clinical learning opportunities outside of the region to increase their birth volume, such as the Inuulitsivik Health Centre or Val-d'Or hospital. Expanding their exposure to different skill sets and environments will better prepare trainees to expect the unexpected. 'In Chisasibi now, we're doing 85% or 90% of pregnancies,' said Chatelain. 'Once a month, students lead a breastfeeding drop-in and it will be up to 30 people showing up. Every time the students do something public, we have an amazing turnout, so the community is really responding to it.' By the end of March, the Chisasibi trainees had accompanied 22 births, 300 pre-natal visits, 177 post-natal visits and 45 school workshops and community health education activities. Pre-natal and post-natal midwifery services expanded to Waskaganish last September, with births expected to begin towards the end of this year. Midwives are already doing 80% of follow-ups. One student began in Waskaganish in March with another to be added when capacity is available. A third birthing hub will eventually be developed in Mistissini. 'In labour, mothers are going right into their maternal language so having people there who can speak with them is incredible,' said Chatelain. 'There's a level of empathy. These students know what it's like to have their baby in Val-d'Or so can connect with these women in a way no other midwife can.' The EIPC program began with a week on the land, making a teepee, gathering medicines and learning traditional ceremonies. Elder Jane Matthew has shared her wealth of lifetime experience, from catching her first baby at about age 7 to her last one three years ago at age 91. 'We did a demonstration of how it was done a long time ago when women gave birth in the teepee,' recalled student Linda Gray. 'There was a placenta ceremony and naming ceremony. That helped me connect with my roots. It was awesome how the course started off.' Gray embodies the commitment of Cree midwives to reclaim the traditional practice, moving from Mistissini last summer to join this first cohort. Coming from a lineage of midwives, Gray has experienced the joy of witnessing babies being born surrounded by their families without having to leave their community. Although there are challenges participating in a program that continues to evolve and being on call all week to meet mothers, Gray wouldn't have it any other way. She believes bringing births back to the territory makes family bonds stronger with young fathers becoming more involved. 'When you catch that baby you're overjoyed,' Gray said. 'My first baby I attended to, I was crying with the little girl there at the birth of her sister. It's magical. We have a planned teepee birth this summer, so I'm excited for that. It will be my first time.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Chicago Tribune
29-05-2025
- Chicago Tribune
CEO pay rose nearly 10% in 2024 as stock prices and profits soared
NEW YORK — The typical compensation package for chief executives who run companies in the S&P 500 jumped nearly 10% in 2024 as the stock market enjoyed another banner year and corporate profits rose sharply. Many companies have heeded calls from shareholders to tie CEO compensation more closely to performance. As a result, a large proportion of pay packages consist of stock awards, which the CEO often can't cash in for years, if at all, unless the company meets certain targets, typically a higher stock price or market value or improved operating profits. The Associated Press' CEO compensation survey, which uses data analyzed for The AP by Equilar, included pay data for 344 executives at S&P 500 companies who have served at least two full consecutive fiscal years at their companies, which filed proxy statements between Jan. 1 and April 30. Here are the key takeaways from the survey: The median pay package for CEOs rose to $17.1 million, up 9.7%. Meanwhile, the median employee at companies in the survey earned $85,419, reflecting a 1.7% increase year over year. CEOs had to navigate sticky inflation and relatively high interest rates last year, as well as declining consumer confidence. But the economy also provided some tail winds: Consumers kept spending despite their misgivings about the economy; inflation did subside somewhat; the Fed lowered interest rates; and the job market stayed strong. The stock market's main benchmark, the S&P 500, rose more than 23% last year. Profits for companies in the index rose more than 9%. '2024 was expected to be a strong year, so the (nearly) 10% increases are commensurate with the timing of the pay decisions,' said Dan Laddin, a partner at Compensation Advisory Partners. Sarah Anderson, who directs the Global Economy Project at the progressive Institute for Policy Studies, said there have been some recent 'long-overdue' increases in worker pay, especially for those at the bottom of the wage scale. But she said too many workers in the world's richest countries still struggle to pay their bills. Rick Smith, the founder and CEO of Axon Enterprises, topped the survey with a pay package valued at $164.5 million. Axon, which makes Taser stun guns and body cameras, saw revenue grow more than 30% for three straight years and posted record annual net income of $377 million in 2024. Axon's shares more than doubled last year after rising more than 50% in 2023. Almost all of Smith's pay package consists of stock awards, which he can only receive if the company meets targets tied to its stock price and operations for the period from 2024 to 2030. Companies are required to assign a value to the stock awards when they are granted. Other top earners in the survey include Lawrence Culp, CEO of what is now GE Aerospace ($87.4 million), Tim Cook at Apple ($74.6 million), David Gitlin at Carrier Global ($65.6 million) and Ted Sarandos at Netflix ($61.9 million). The bulk of those pay packages consisted of stock or options awards. The median stock award rose almost 15% last year compared to a 4% increase in base salaries, according to Equilar. 'For CEOs, target long-term incentives consistently increase more each year than salaries or bonuses,' said Melissa Burek, also a partner at Compensation Advisory Partners. 'Given the significant role that long-term incentives play in executive pay, this trend makes sense.' Jackie Cook at Morningstar Sustainalytics said the benefit of tying CEO pay to performance is 'that share-based pay appears to provide a clear market signal that most shareholders care about.' But she notes that the greater use of share-based pay has led to a 'phenomenal rise' in CEO compensation 'tracking recent years' market performance,' which has 'widened the pay gap within workplaces.' Some well-known billionaire CEOs are low in the AP survey. Warren Buffett's compensation was valued at $405,000, about five times what a worker at Berkshire Hathaway makes. According to Tesla's proxy, Elon Musk received no compensation for 2024, but in 2018 he was awarded a multiyear package that has been valued at $56 billion and is the subject of a court battle. Other notable CEOs didn't meet the criteria for inclusion the survey. Starbucks' Brian Niccol received a pay package valued at $95.8 million, but he only took over as CEO on Sept. 9. Nvidia's Jensen Huang saw his compensation grow to $49.9 million, but the company filed its proxy after April 30. At half the companies in AP's annual pay survey, it would take the worker at the middle of the company's pay scale 192 years to make what the CEO did in one. Companies have been required to disclose this so-called pay ratio since 2018. The pay ratio tends to be highest at companies in industries where wages are typically low. For instance, at cruise line company Carnival Corp., its CEO earned nearly 1,300 times the median pay of $16,900 for its workers. McDonald's CEO makes about 1,000 times what a worker making the company's median pay does. Both companies have operations that span numerous countries. Overall, wages and benefits netted by private-sector workers in the U.S. rose 3.6% through 2024, according to the Labor Department. The average worker in the U.S. makes $65,460 a year. That figure rises to $92,000 when benefits such as health care and other insurance are included. 'With CEO pay continuing to climb, we still have an enormous problem with excessive pay gaps,' Anderson said. 'These huge disparities are not only unfair to lower-level workers who are making significant contributions to company value – they also undercut enterprise effectiveness by lowering employee morale and boosting turnover rates.' For the 27 women who made the AP survey — the highest number dating back to 2014 — median pay rose 10.7% to $20 million. That compares to a 9.7% increase to $16.8 million for their male counterparts. The highest earner among female CEOs was Judith Marks of Otis Worldwide, with a pay package valued at $42.1 million. The company, known for its elevators and escalators, has had operating profit above $2 billion for four straight years. About $35 million of Marks' compensations was in the form of stock awards. Other top earners among female CEOs were Jane Fraser of Citigroup ($31.1 million), Lisa Su of Advanced Micro Devices ($31 million), Mary Barra at General Motors ($29.5 million) and Laura Alber at Williams-Sonoma ($27.7 million). Christy Glass, a professor of sociology at Utah State University who studies equity, inclusion and leadership, said while there may be a few more women on the top paid CEO list, overall equity trends are stagnating, particularly as companies cut back on DEI programs. 'There are maybe a couple more names on the list, but we're really not moving the needle significantly,' she said. Equilar found that a larger number of companies are offering security perquisites as part of executive compensation packages, possibly in reaction to the December shooting of UnitedHealthCare CEO Brian Thompson. Equilar said an analysis of 208 companies in the S&P 500 that filed proxy statements by April 2 showed that the median spending on security rose to $94,276 last year from $69,180 in 2023. Among the companies that increased their security perks were Centene, which provides health care services to Medicare and Medicaid, and the chipmaker Intel.
